Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pandion Therapeutics appoints Rahul Kakkar, MD, as Chief Executive Officer. http://www.businesswire.com/news/home/20190717005190/en/Pandion-Therapeutics-Appoints-Rahul-Kakkar-MD-Chief/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer

Recent Articles

A History of Pharmaceutical Innovation In Mexico from 1950 to 2020

Moderna Reaffirms Commitment to Job Creation in Massachusetts

Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium...

Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia